Sign In  |  Register  |  About Los Altos  |  Contact Us

Los Altos, CA
September 01, 2020 1:26pm
7-Day Forecast | Traffic

  • Search Hotels in Los Altos

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc Ord (OP: AZNCF )

133.93 +7.87 (+6.24%)
Streaming Delayed Price Updated: 3:26 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Astrazeneca Plc Ord

< Previous 1 2 3 4 5 6 7 8 9 Next >
AstraZeneca Abandons Blood Cancer, Cardiovascular Programs Amid Portfolio Prioritization
Earlier today, AstraZeneca plc (NASDAQ: AZN)  
Via Benzinga
AstraZeneca Q2 Earnings Beat Consensus Despite Zero COVID-19 Vaccine Sales, Stock Shoots Up
AstraZeneca Plc's (NASDAQ: AZN) unit Alexion has  
Via Benzinga
AstraZeneca-Sanofi's Respiratory Syncytial Virus Treatment Scores FDA Approval To Prevent Infection In Infants
The FDA approved AstraZeneca Plc (NASDAQ: 
Via Benzinga
AstraZeneca Shares Under Pressure On Some Adverse Events In Late-Stage Lung Cancer Drug Trial
AstraZeneca Plc (NASDAQ: AZN) reported high-level results from the TROPION-Lung01 Phase 3 trial of datopotamab deruxtecan (Dato-DXd) in patients with locally advanced or metastatic non-small cell lung... 
Via Benzinga
AstraZeneca's Imfinzi/Imjudo Combo Shows Sustained Overall Survival Benefit At Four Years In Liver Cancer
AstraZeneca Plc (NASDAQ: AZN) released updated results from the HIMALAYA Phase 3 trial evaluating Imfinzi (durvalumab) plus Imjudo (tremelimumab-actl) in unresectable hepatocellular carcinoma (HCC)... 
Via Benzinga
AstraZeneca Seeks Expanded Use For Soliris As First Targeted Therapy For Pediatric Patients With Autoimmune Neuromuscular Disease
The European Union has reco 
Via Benzinga
Why Are Pieris Pharmaceuticals Shares Tanking Today
Pieris Pharmaceuticals Inc (NASDAQ: PIRS) announced that partner AstraZeneca plc (NASDAQ: AZN) decided to discontinue and cease dosing in the ongoing clinical studies of elarekibep, an inhaled IL-4... 
Via Benzinga
AstraZeneca Mulls China Business Unit Spin-Off Amid Geopolitical Tensions
European drugmaker AstraZeneca plc (NASDAQ: AZN) is reportedly drafting a plan to spin off its China business, and listing a separate unit in Hong Kong is considered an option amid mounting... 
Via Benzinga
AstraZeneca's Add On Treatment With Standard Care Improves Hemoglobin Levels In Rare Blood Disorder
AstraZeneca Plc (NASDAQ: AZN)  
Via Benzinga
AstraZeneca Inks Over $2B Agreement For Cell Therapies Targeting Diabetes
AstraZeneca plc (NASDAQ: AZN) has entered into a 
Via Benzinga
Unanimous Support for AstraZeneca and Sanofi's Nirsevimab: Next Generation RSV Treatment on the Horizon
The FDA's Antimicrobial Drugs Advisory Committee has voted unanimously 21 to 0 that AstraZeneca plc (NASDAQ: AZN) and Sanofi SA's (NASDAQ: SNY) nirsevimab has a favorable benefit-risk profile t 
Via Benzinga
AstraZeneca's Tagrisso Significantly Enhances Survival in Certain Post Surgery Non-Small Cell Lung Cancer Patients
Via Benzinga
AstraZeneca/Merck's Cancer Drug Combo Shows Positive Results In Endometrial Cancer
Via Benzinga
AstraZeneca's China Executive Seeks Loyalty to "Love the Communist Party" In China
During an event held in the city of Wuxi to commemorate its 30th year in China, AstraZeneca Plc's (NASDAQ: AZN) China president, Wang Lei, said the company will seek to be a patriotic company in China... 
Via Benzinga
One More Quits US Pharma Lobby Group: AstraZeneca Follows Teva, AbbVie Footsteps
AstraZeneca Plc (NASDAQ: AZN) has decided to leave a U.S. drug lobby group, the Pharmaceutical Research and Manufacturers of America (PhRMA), making it the third company to leave the group in the last... 
Via Benzinga
AstraZeneca' Tagrisso/Chemo Combo Therapy Delays Treatment Resistance, Disease Progression In Certain Type Of Advanced Lung Cancer
AstraZeneca Plc (NASDAQ: AZN) has reported topline data 
Via Benzinga
Sanofi, AstraZeneca Release Real-World Data For Respiratory Syncytial Virus Antibody
The race to tap the respiratory syncytial virus (RSV) this season intensifies as Sanofi SA (NASDAQ: SNY) and AstraZeneca Plc (NASDAQ: AZN) have  
Via Benzinga
FDA Advisory Committee Votes Favoring Restricted Use Of AstraZeneca/Merck's Prostate Cancer Drug
Via Benzinga
FDA Casts Doubt on Merck/AstraZeneca's Cancer Drug for Prostate Cancer Ahead of Adcomm Meeting
The FDA's Oncologic Drugs Advisory Committee will be meeting tomorrow, Friday, 28 April, to discuss the supplemental new drug application (sNDA) for Lynparza (olaparib) in combination with abiraterone... 
Via Benzinga
AstraZeneca's COVID-19 Vaccine Loses Shine, Cancer Drug Imfinzi & Emerging Markets Stabilize Q1 Revenues
AstraZeneca Plc (NASDAQ: AZN) has reported Q1 FY23 core EPS of $1.92, up 1% Y/Y (+6% on constant currency), better than the consensus of $1.07. The company clocked Q1 sales of $10.88 billion, -4% (flat... 
Via Benzinga
AstraZeneca, Ionis Unveil Complete Phase 3 Data For ATTR Candidate, Says Drug Halts Disease Progression
Via Benzinga
Why AstraZeneca Shares Are Trading Higher Today?
AstraZeneca plc's (NASDAQ: AZN) vaccine head highlighted the confidence that the company's new COVID-19 antibody treatment could protect immunocompromised patients against all known virus variants. 
Via Benzinga
Canadian Cancer Diagnostic Company BioMark Working On Early Lung Detection Assay
Via Benzinga
AstraZeneca' Cancer Drug Combo Meets Goal In Late-Stage Ovarian Cancer Study
Via Benzinga
Pieris Pharma Pushes Elarekibep Data Readout, Investors React Negatively
Via Benzinga
AstraZeneca Axes Pneumonia Drug Pact With Aridis
AstraZeneca plc (NASDAQ: AZN) scrapped its license agreement with Aridis Pharmaceuticals Inc (NASDAQ: ARDS). 
Via Benzinga
AstraZeneca-Ionis Partnered Rare Disease Drug Data Shows Sustained Benefit; Drug Under FDA Review
Via Benzinga
AstraZenceca's Tagrisso Shows Survival Benefit In Early-Stage Lung Cancer Settings
Via Benzinga
AstraZeneca's Immunotherapy Imfinzi Shows Improvement In Survival Chances In Lung Cancer Patients
Via Benzinga
AstraZeneca-Daiichi Sankyo's Flagship Cancer Drug Shows Meaningful, Durable Responses In Other Solid Tumor Setting
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 LosAltos.com & California Media Partners, LLC. All rights reserved.